Activity Details

Accredited By

This continuing medical education activity is provided by Vindico Medical Education.

Activity Chair

Anthony P. Fernandez, MD, PhD
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Departments of Dermatology and Pathology
Co-Medical Director of Continuing Medical Education
Cleveland Clinic
Cleveland, OH

• Disclosure: Principal Investigator (paid to institution): Roche

Faculty

Thomas P. Sollecito, DMD, FDS, RCSEd
Professor and Chair of Oral Medicine
Associate Dean of Hospital Affairs
University of Pennsylvania
School of Dental Medicine
Chief of Oral Medicine
University of Pennsylvania Health System
Philadelphia, PA

• Disclosure: Contracted Research: AFYX Therapeutics

Victoria Werth, MD
Professor of Dermatology and Medicine 
Chief, Dermatology
Hospital of the University of Pennsylvania
Veteran’s Administration Medical Center 
Philadelphia, PA

• Disclosure: Consulting Fee: Amgen, Biogen, Bristol-Myers Squibb, Celgene, Crisalis, CSL Behring, EMD Serono, Genentech, Gilead, Idera, Incyte, Janssen, Lilly, MedImmune, Medscape, Nektar, Pfizer, Principia, Resolve, Vielo
  Contracted Research: AstraZeneca, Biogen, Celgene, Corbus, Genentech, Gilead, Janssen, Pfizer, Vielo

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Activity Description

Autoimmune bullous diseases involve autoimmunity against structural components that maintain cell-cell and cell-matrix adhesion in the skin and mucous membranes. Such diseases include those in which blistering occurs at the basement membrane zone and those in which blistering occurs within the epidermis. Of these, pemphigus involves both the skin and mucosal membranes. Pemphigus vulgaris (PV) is, by far, the most common subtype, accounting for approximately 80% of all pemphigus cases. This rare, chronic disease affects approximately 30,000 to 40,000 individuals in the United States and can have a significant impact on quality of life. In this continuing education activity, expert clinicians will examine the epidemiology, diagnosis, and treatment of PV, as well as effective approaches for the multidisciplinary care of patients with PV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Summarize the characteristics, epidemiology, and impact of pemphigus vulgaris (PV) on patients’ quality of life
• Assess the benefits and limitations of conventional and newer treatment strategies for PV
• Implement effective approaches for the multidisciplinary care of patients with PV

Target Audience

The intended audience for the activity is dermatologists and other health care professionals involved in the treatment of patients with pemphigus vulgaris.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity:
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the Merit-Based Incentive Payment System (MIPS) of QPP, accredited CME providers need to implement activities that:

• address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
• have specific, measurable aim(s) for improvement;
• include interventions intended to result in improvement;
• include data collection and analysis of performance data to assess the impact of the interventions; and
• define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Disclaimer

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing medical education activity is provided by Vindico Medical Education.

Activity Chair

Anthony P. Fernandez, MD, PhD
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Departments of Dermatology and Pathology
Co-Medical Director of Continuing Medical Education
Cleveland Clinic
Cleveland, OH

• Disclosure: Principal Investigator (paid to institution): Roche

Faculty

Thomas P. Sollecito, DMD, FDS, RCSEd
Professor and Chair of Oral Medicine
Associate Dean of Hospital Affairs
University of Pennsylvania
School of Dental Medicine
Chief of Oral Medicine
University of Pennsylvania Health System
Philadelphia, PA

• Disclosure: Contracted Research: AFYX Therapeutics

Victoria Werth, MD
Professor of Dermatology and Medicine 
Chief, Dermatology
Hospital of the University of Pennsylvania
Veteran’s Administration Medical Center 
Philadelphia, PA

• Disclosure: Consulting Fee: Amgen, Biogen, Bristol-Myers Squibb, Celgene, Crisalis, CSL Behring, EMD Serono, Genentech, Gilead, Idera, Incyte, Janssen, Lilly, MedImmune, Medscape, Nektar, Pfizer, Principia, Resolve, Vielo
  Contracted Research: AstraZeneca, Biogen, Celgene, Corbus, Genentech, Gilead, Janssen, Pfizer, Vielo

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Activity Description

Autoimmune bullous diseases involve autoimmunity against structural components that maintain cell-cell and cell-matrix adhesion in the skin and mucous membranes. Such diseases include those in which blistering occurs at the basement membrane zone and those in which blistering occurs within the epidermis. Of these, pemphigus involves both the skin and mucosal membranes. Pemphigus vulgaris (PV) is, by far, the most common subtype, accounting for approximately 80% of all pemphigus cases. This rare, chronic disease affects approximately 30,000 to 40,000 individuals in the United States and can have a significant impact on quality of life. In this continuing education activity, expert clinicians will examine the epidemiology, diagnosis, and treatment of PV, as well as effective approaches for the multidisciplinary care of patients with PV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Summarize the characteristics, epidemiology, and impact of pemphigus vulgaris (PV) on patients’ quality of life
• Assess the benefits and limitations of conventional and newer treatment strategies for PV
• Implement effective approaches for the multidisciplinary care of patients with PV

Target Audience

The intended audience for the activity is dermatologists and other health care professionals involved in the treatment of patients with pemphigus vulgaris.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity:
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the Merit-Based Incentive Payment System (MIPS) of QPP, accredited CME providers need to implement activities that:

• address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
• have specific, measurable aim(s) for improvement;
• include interventions intended to result in improvement;
• include data collection and analysis of performance data to assess the impact of the interventions; and
• define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Disclaimer

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

Target Audience

This educational initiative is intended for primary care clinicians who care for adult patients with SLE.

Learning Objectives

1. Describe key evidence-based strategies for diagnosing SLE.
2. Utilize effective strategies to assess and co-manage patients with SLE over time.
3. Summarize key aspects of established treatments for SLE.
4. Monitor the patient for treatment side effects.
5. Formulate a plan for communication with patients about SLE and its treatment, including methods for facilitating treatment adherence.

Activity Description

Autoimmune diseases are difficult to diagnose. Lupus, in particular, is complicated as its symptoms are common to a variety of other conditions. Diagnosing lupus with any degree of accuracy can be challenging and costly. This activity will orient the primary care provider on how to accurately diagnose systemic lupus erythematosus (SLE), further providing guidance on management strategies and doctor-patient communication, specifically with the goal of increasing treatment adherence in patients.

Agenda

1. Recognizing SLE: Primary Care Approach to Diagnostic Criteria
   How to recognize the condition based on ACR criteria.
2. Assessing a Moving Target: SLE Evaluation Over Time
   Signs of disease progression; when to recommend further evaluation.
3. Answering the “Whats” and “Whens” of Management
   Understanding treatment options, facilitating specialist consultation, and monitoring for treatment side effects.
4. Keeping the Lines Open: Practical Strategies for Communication and Facilitating Adherence
   What are effective communication techniques (eg, AHRQ’s “Teach Back” method, particular phrasing for adherence-related questions, encouraging patient-generated questions) that can address sensitive or challenging issues? Applying practical patient-centered approaches as a means to facilitate treatment adherence.

Faculty

Louis Kuritzky, MD
Content Creator and Activity Presenter
Clinical Assistant Professor Emeritus
Department of Community Health and Family Medicine
University of Florida, Gainesville
Gainesville, Florida

Disclosure:
Louis Kurtizky, MD, has no relevant financial relationships to disclose.

Daniel J. Wallace, MD, FACP, MACR
Content Creator
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
In affiliation with Attune Health
Los Angeles, California

Disclosure:
Daniel J. Wallace, MD, FACP, MACR, has served as an advisor for Amgen, EMD Serono, Celgene, Merck, Lilly.

MOC Reviewer

Richard Sadovsky, MD, MS
Associate Professor of Family Medicine
SUNY-Downstate Medical center

Disclosure:
Richard Sadovsky, MD, has no relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. The France Foundation resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, The France Foundation seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. The France Foundation is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Instructions for Receiving Credit

• There are no fees for participating in and receiving credit for this activity.
• Review the activity objectives and CME/CE information.
• Complete the CME/CE activity.
• Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
• Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
• Credit documentation/reporting:
• • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
  • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation requires CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. The France Foundation does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions about the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Accredited By

Target Audience

This educational initiative is intended for primary care clinicians who care for adult patients with SLE.

Learning Objectives

1. Describe key evidence-based strategies for diagnosing SLE.
2. Utilize effective strategies to assess and co-manage patients with SLE over time.
3. Summarize key aspects of established treatments for SLE.
4. Monitor the patient for treatment side effects.
5. Formulate a plan for communication with patients about SLE and its treatment, including methods for facilitating treatment adherence.

Activity Description

Autoimmune diseases are difficult to diagnose. Lupus, in particular, is complicated as its symptoms are common to a variety of other conditions. Diagnosing lupus with any degree of accuracy can be challenging and costly. This activity will orient the primary care provider on how to accurately diagnose systemic lupus erythematosus (SLE), further providing guidance on management strategies and doctor-patient communication, specifically with the goal of increasing treatment adherence in patients.

Agenda

1. Recognizing SLE: Primary Care Approach to Diagnostic Criteria
   How to recognize the condition based on ACR criteria.
2. Assessing a Moving Target: SLE Evaluation Over Time
   Signs of disease progression; when to recommend further evaluation.
3. Answering the “Whats” and “Whens” of Management
   Understanding treatment options, facilitating specialist consultation, and monitoring for treatment side effects.
4. Keeping the Lines Open: Practical Strategies for Communication and Facilitating Adherence
   What are effective communication techniques (eg, AHRQ’s “Teach Back” method, particular phrasing for adherence-related questions, encouraging patient-generated questions) that can address sensitive or challenging issues? Applying practical patient-centered approaches as a means to facilitate treatment adherence.

Faculty

Louis Kuritzky, MD
Content Creator and Activity Presenter
Clinical Assistant Professor Emeritus
Department of Community Health and Family Medicine
University of Florida, Gainesville
Gainesville, Florida

Disclosure:
Louis Kurtizky, MD, has no relevant financial relationships to disclose.

Daniel J. Wallace, MD, FACP, MACR
Content Creator
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
In affiliation with Attune Health
Los Angeles, California

Disclosure:
Daniel J. Wallace, MD, FACP, MACR, has served as an advisor for Amgen, EMD Serono, Celgene, Merck, Lilly.

MOC Reviewer

Richard Sadovsky, MD, MS
Associate Professor of Family Medicine
SUNY-Downstate Medical center

Disclosure:
Richard Sadovsky, MD, has no relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. The France Foundation resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, The France Foundation seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. The France Foundation is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Instructions for Receiving Credit

• There are no fees for participating in and receiving credit for this activity.
• Review the activity objectives and CME/CE information.
• Complete the CME/CE activity.
• Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
• Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
• Credit documentation/reporting:
• • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
  • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation requires CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. The France Foundation does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions about the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.